MEI Pharma reports FY15 results

• MEI Pharma (NASDAQ:MEIP) FY15 results: Revenues: $1M (0.0%); COGS: $1M (0.0%); R&D Expense: $23.8M (23.3%); SG&A: $8.9M (12.7%); Operating Income: $-32.8M (20.6%); Net Income: $-32.7M (20.7%); EPS: $-1.16 (-14.1%); Quick Assets: $63.8M (30.7%).
• No guidance given.